Clinical Trial Update: A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating camrelizumab plus famitinib as subsequent therapy in advanced NSCLC was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Famitinib (Famitinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Advanced NSCLC | Phase 3 | Status: TERMINATED